Steve Grzanich has the business news of the day with the Wintrust Business Minute. Pure Lithium is moving to Chicago. The next-generation battery technology company will relocate its entire ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

President Donald Trump has sent letters to 14 countries outlining higher tariffs they’ll face if they don’t make trade deals ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

The S&P 500 climbed 0.61% on Wednesday (July 9), driven by gains in tech stocks as Nvidia hit a historic milestone and ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...